This Phase II, open-label, multi-drug, multi-center platform study consists of individual sub-studies/cohorts, each allows the assessment of multiple novel agents or novel combinations.
Participants will be assigned across different sub-studies/cohorts, to have sufficient evaluable participants of the confirmed recommended dose by Safety Review Committee (SRC) for study intervention in each corresponding sub-study/cohort.
